Sertraline had a mild inhibitory effect on the metabolism of diazepam, tolbutamide and warfarin, which are substrates of CYP2C9 or CYP2C19; The clinical relevance of this effect was unclear. [7] As predicted from in vitro data, sertraline did not alter human metabolism of CYP3A4 substrates, erythromycin, alprazolam, carbamazepine, clonazepam and terfenadine; nor did it affect the metabolism of clozapine, a substrate of CYP1A2. [7] [19] [102] [6] Nausea, ejaculatory insufficiency, insomnia, diarrhea, dry mouth, drowsiness, dizziness, tremors, headache, excessive sweating, fatigue and decreased libido are the most common side effects of sertraline with the greatest difference with placebo. Next, you should have the facts of your situation reviewed by a lawyer experienced in drugs and medical devices. This allows you to protect any legal claims you may have and focus your energies on healing yourself and your family. A 2019 systematic review suggested that sertraline may be a good way to control anger, irritability, and hostility in depressed patients and patients with other comorbidities. [65] Like other SSRIs, sertraline is associated with sexual side effects, including sexual arousal disorder, erectile dysfunction, and difficulty reaching orgasm. Although nefazodone and bupropion had no negative effect on sexual function, 67% of men on sertraline had difficulty ejaculation compared to 18% before treatment. [83] Sexual arousal disorders, defined as «insufficient lubrication and swelling in women and erectile difficulties in men,» occurred in 12% of people on sertraline, compared with 1% of patients on placebo.
Improved mood due to sertraline treatment sometimes counterbalanced these side effects, so sexual desire and overall satisfaction with sex remained the same as before sertraline treatment. However, under the action of the placebo, desire and satisfaction improved slightly. [84] Some people continue to experience sexual side effects after they stop taking SSRIs. [85] Until 2002, sertraline was only approved for use in adults 18 years of age and older; This year, it was approved by the FDA for the treatment of children 6 years of age and older with major OCD. In 2003, the UK Medicines and Healthcare Products Regulatory Agency published a guideline stating that SSRIs other than fluoxetine (Prozac) are not suitable for the treatment of depression in patients under 18 years of age. [133] [134] However, sertraline can still be used in the UK to treat obsessive-compulsive disorder in children and adolescents. [135] In 2005, the FDA added a warning about pediatric suicidal behavior to all antidepressants, including sertraline. The development of tametraine was quickly stopped due to adverse stimulant effects in animals. A few years later, in 1977, pharmacologist Kenneth Koe became interested in the tametrin series after comparing the structural characteristics of a variety of reuptake inhibitors. He asked another Pfizer chemist, Willard Welch, to synthesize some previously unexplored tametramine derivatives. Welch produced a number of potent norepinephrine and triple reuptake inhibitors, but to the surprise of scientists, a representative of the generally inactive cis analogues was a serotonin reuptake inhibitor.
Welch then produced stereoisomers of this compound, which were tested in vivo by animal behaviorist Albert Weissman. The strongest and most selective isomer (+) was developed and eventually called sertraline. Weissman and Koe recalled that the group was not set up to make an SSRI-type antidepressant – in that sense, their investigation was not «very goal-oriented» and the discovery of the sertraline molecule was a happy coincidence. According to Welch, they worked outside the mainstream at Pfizer and didn`t even have «any formal project team.» The group had to overcome the initial bureaucratic reluctance to pursue the development of sertraline as Pfizer considered approving an antidepressant candidate from another company. [126] [128] [129] The FDA requires all antidepressants, including sertraline, to carry a warning box stating that antidepressants increase the risk of suicide in people under the age of 25.